Dr Shah Discusses HER-RAM Study Results in HER2+ GI Cancers
06/15/2021
Manish Shah, MD, highlights the multi-center, phase 1b/2 study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study), presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.